Related Experiment Video
Updated: May 14, 2026

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis
Published on: July 28, 2023
CD271(+) bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis
Bikul Das1, Suely S Kashino, Ista Pulu
1Division of Oncology, Departments of Medicine and Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA. bikuldas@stanford.edu
Abstract:
Mycobacterium tuberculosis (Mtb) can persist in hostile intracellular microenvironments evading immune cells and drug treatment. However, the protective cellular niches where Mtb persists remain unclear. We report that Mtb may maintain long-term intracellular viability in a human bone marrow (BM)-derived CD271(+)/CD45(-) mesenchymal stem cell (BM-MSC) population in vitro. We also report that Mtb resides in an equivalent population of BM-MSCs in a mouse model of dormant tuberculosis infection. Viable Mtb was detected in CD271(+)/CD45(-) BM-MSCs isolated from individuals who had successfully completed months of anti-Mtb drug treatment. These results suggest that CD271(+) BM-MSCs may provide a long-term protective intracellular niche in the host in which dormant Mtb can reside.
Related Concept Videos
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Mesenchymal Stem Cells

